Reata Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company based in Irving, Texas. The firm was founded in 2002 and was originally known as Reata Discovery before it changed its name to Reata Pharmaceuticals Inc. in 2005. Operating globally, the firm is primarily engaged in the discovery, development, and commercialisation of a range of novel therapies for life threatening diseases that traditionally have no, or highly limited, treatment options.
Diseases that the firm targets include neurological conditions such as Friedreich's ataxia (FA) and diabetic peripheral neuropathic pain (DPNP), as well as a number of chronic kidney diseases such as Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), rapid progressing CKD, and focal segmental glomerulosclerosis (FSGS).
The company’s product candidates are bardoxolone methyl and omaveloxolone, which work by activating the transcription factor Nrf2 to restore mitochondrial function, decrease oxidative stress, and eliminate chronic inflammation. The firm’s inflammation-modulating drugs have a number of applications in the treatment of renal, cardiovascular, and autoimmune diseases. The firm went public in 2016 and trades on the NASDAQ, where it is listed under the ticker RETA. |
